Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Donates A Second-line Defense Against China's Swelling Multidrug-resistant Tuberculosis

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Shoring up China's arsenal against multidrug-resistant tuberculosis, Bayer AG will donate 620,000 tablets of a broad-spectrum antibiotic used as part of a second-line TB regimen

You may also be interested in...



Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?

SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict

Bayer Says India's Natco Has No Ground For Compulsory License; Blames Lack of Drug Availability On Poor Health Infrastructure

MUMBAI - As Natco Pharma Ltd. is set to test the viability of India's highly debated compulsory licensing provisions by challenging Bayer AG's kidney and liver cancer treatment Nexavar (sorafenib), the German polymers-to-pharmaceuticals conglomerate has said that "extensive use of compulsory licenses will in the long-term undermine and threaten the patent system.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel